Search - tctmd.com

Displaying 161 - 180 of 212

Sort: Relevancy | Date

News Daily News

In-Hospital Switching of Antiplatelet Agents in MI Patients Relatively Common, Driven by Patient Risk, Other Factors

L.A. McKeown

August 20, 2014

News Daily News

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

Todd Neale

August 20, 2014

News Daily News

TCTMD’s Top 10 Most Popular News Stories for 2013

Jason Kahn

January 27, 2014

News Daily News

Preconditioning May Counteract Platelet Increase Associated with RF Ablation in A-fib

L.A. McKeown

December 30, 2013

News Conference News ESC 2013

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Yael L. Maxwell

September 03, 2013

News Conference News ESC 2013

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

Yael L. Maxwell

September 01, 2013

News Daily News

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

August 30, 2013

News Daily News

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

July 24, 2013

News Daily News

Danish Registry Suggests Aspirin Unnecessary in A-fib Patients After MI or PCI

Caitlin E. Cox

June 20, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

News Conference News ACC 2013

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Yael L. Maxwell

March 09, 2013

News Daily News

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

February 27, 2013

News Daily News

Clopidogrel Pretreatment Reduces Cardiac Events, Not Mortality, After PCI

Yael L. Maxwell

December 19, 2012

News Daily News

Risk Peaks Early After Clopidogrel Cessation in SVG PCI Patients

November 13, 2012

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

Presentation TCT 2012

Part 2: Antiplatelet Agents

Presenter: Robert Harrington

October 25, 2012

Presentation

Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an ACS

Presenter: Andr?s Kom?csi

October 01, 2012

News Daily News

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

L.A. McKeown

September 18, 2012

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

News Daily News

Timing of Platelet Testing Key to Optimal Therapy After PCI for ACS

L.A. McKeown

August 20, 2012

Advertisement

In-Hospital Switching of Antiplatelet Agents in MI Patients Relatively Common, Driven by Patient Risk, Other Factors

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

TCTMD’s Top 10 Most Popular News Stories for 2013

Preconditioning May Counteract Platelet Increase Associated with RF Ablation in A-fib

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

Danish Registry Suggests Aspirin Unnecessary in A-fib Patients After MI or PCI

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

Clopidogrel Pretreatment Reduces Cardiac Events, Not Mortality, After PCI

Risk Peaks Early After Clopidogrel Cessation in SVG PCI Patients

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Part 2: Antiplatelet Agents

Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an ACS

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

Timing of Platelet Testing Key to Optimal Therapy After PCI for ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content